Durable Complete Response to Nivolumab in a Patient with HIV and Metastatic Non-small Cell Lung Cancer

Overview

Journal J Thorac Dis

Publisher AME Publishing Company

Specialty Pulmonary Medicine

Date 2017 Jul 26

PMID 28740692

Citations 10

Authors

Brennan McCullar

Taylor Alloway

Michael Martin

Affiliations

Soon will be listed here.

Abstract

Programmed death 1 (PD-1) inhibitors have been shown to increase overall survival in non-small cell lung cancer (NSCLC) patients. HIV patients have increased expression of PD-1 on their T-cell surfaces. We describe a patient with well-controlled HIV and NSCLC who underwent treatment with nivolumab and had a durable complete response (CR) with his viral load remaining undetectable. To date there is only one case report of a cancer patient with melanoma and with HIV treated with a programmed death ligand 1 (PD-L1) inhibitor. The majority of clinical trials involving PD-1 and PD-L1 inhibitors exclude HIV patients.

Citing Articles

Pembrolizumab in an HIV-infected patient with glioblastoma.

Yuen C, Bao S, Pekmezci M, Mo F, Kong X Immunotherapy. 2024; 16(12):803-811.

PMID: 38889068 PMC: 11457652. DOI: 10.1080/1750743X.2024.2362566.

Expression Profile and Biological Role of Immune Checkpoints in Disease Progression of HIV/SIV Infection.

Sun Y, Xue J Viruses. 2022; 14(3).

PMID: 35336991 PMC: 8955100. DOI: 10.3390/v14030581.

Risk factors for immune-related adverse events: what have we learned and what lies ahead?.

Liu X, Shi Y, Zhang D, Zhou Q, Liu J, Chen M Biomark Res. 2021; 9(1):79.

PMID: 34732257 PMC: 8565046. DOI: 10.1186/s40364-021-00314-8.

Infections and Immunotherapy in Lung Cancer: A Bad Relationship?.

Belluomini L, Caldart A, Avancini A, Dodi A, Trestini I, Kadrija D Int J Mol Sci. 2020; 22(1).

PMID: 33375194 PMC: 7793072. DOI: 10.3390/ijms22010042.

Lung Cancer (LC) in HIV Positive Patients: Pathogenic Features and Implications for Treatment.

Frega S, Ferro A, Bonanno L, Guarneri V, Conte P, Pasello G Int J Mol Sci. 2020; 21(5).

PMID: 32111093 PMC: 7084664. DOI: 10.3390/ijms21051601.

References

Borghaei H, Paz-Ares L, Horn L, Spigel D, Steins M, Ready N . Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(17):1627-39. PMC: 5705936. DOI: 10.1056/NEJMoa1507643. View

Davar D, Wilson M, Pruckner C, Kirkwood J . PD-1 Blockade in Advanced Melanoma in Patients with Hepatitis C and/or HIV. Case Rep Oncol Med. 2015; 2015:737389. PMC: 4581502. DOI: 10.1155/2015/737389. View

Sundar R, Cho B, Brahmer J, Soo R . Nivolumab in NSCLC: latest evidence and clinical potential. Ther Adv Med Oncol. 2015; 7(2):85-96. PMC: 4346216. DOI: 10.1177/1758834014567470. View

Grabmeier-Pfistershammer K, Steinberger P, Rieger A, Leitner J, Kohrgruber N . Identification of PD-1 as a unique marker for failing immune reconstitution in HIV-1-infected patients on treatment. J Acquir Immune Defic Syndr. 2010; 56(2):118-24. DOI: 10.1097/QAI.0b013e3181fbab9f. View

Pardoll D . The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012; 12(4):252-64. PMC: 4856023. DOI: 10.1038/nrc3239. View

Hamid O, Robert C, Daud A, Hodi F, Hwu W, Kefford R . Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med. 2013; 369(2):134-44. PMC: 4126516. DOI: 10.1056/NEJMoa1305133. View

Kazandjian D, Suzman D, Blumenthal G, Mushti S, He K, Libeg M . FDA Approval Summary: Nivolumab for the Treatment of Metastatic Non-Small Cell Lung Cancer With Progression On or After Platinum-Based Chemotherapy. Oncologist. 2016; 21(5):634-42. PMC: 4861371. DOI: 10.1634/theoncologist.2015-0507. View

Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C . Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncol. 2015; 16(8):908-18. PMC: 9004487. DOI: 10.1016/S1470-2045(15)00083-2. View

Brahmer J, Reckamp K, Baas P, Crino L, Eberhardt W, Poddubskaya E . Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015; 373(2):123-35. PMC: 4681400. DOI: 10.1056/NEJMoa1504627. View

10.

Velu V, Shetty R, Larsson M, Shankar E . Role of PD-1 co-inhibitory pathway in HIV infection and potential therapeutic options. Retrovirology. 2015; 12:14. PMC: 4340294. DOI: 10.1186/s12977-015-0144-x. View

11.

Macatangay B, Rinaldo C . PD-1 blockade: A promising immunotherapy for HIV?. Cellscience. 2010; 5(4):61-65. PMC: 2872789. View

12.

Porichis F, Kwon D, Zupkosky J, Tighe D, McMullen A, Brockman M . Responsiveness of HIV-specific CD4 T cells to PD-1 blockade. Blood. 2011; 118(4):965-74. PMC: 3148173. DOI: 10.1182/blood-2010-12-328070. View

13.

Brahmer J, Tykodi S, Chow L, Hwu W, Topalian S, Hwu P . Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012; 366(26):2455-65. PMC: 3563263. DOI: 10.1056/NEJMoa1200694. View